Vildagliptin and the Glucagon Response to Hypoglycemia in Insulin-Treated Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore whether the novel therapy of type 2 diabetes,
vildagliptin, which inhibits dipeptidyl peptidase-4 (DPP-4), affects glucagon
counterregulation during hypoglycemia in insulin-treated patients with type 2 diabetes.
Vildagliptin is given, together with the on-going insulin therapy, for one month, whereafter
hypoglycemia is induced under standardized conditions, and the glucagon response is
determined, and compared to that after a month of placebo treatment.